BRIEF-Antisoma leukaemia drug gets U.S. fast track status

LONDON, June 3 (Reuters) - Antisoma PLC:

* FDA has granted fast track designation to AS1413 for treatment of secondary

acute myeloid leukaemia

((London Equities Newsroom; [phone]))

(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.